Best's Market Segment Report: AM Best Maintains Negative Outlook on Italy's Life Insurance Segment
AMSTERDAM, May 28, 2025--(BUSINESS WIRE)--AM Best is maintaining its negative outlook on Italy's life insurance segment.
In its new Best's Market Segment Report, "Market Segment Outlook: Italy Life Insurance", AM Best notes that while it expects premium growth momentum to continue in 2025, insurers in Italy are still facing elevated levels of surrenders which failed to scale down as hoped. These surrenders continue to exert pressure on net flows, especially with regards to capital-light products.
The report also states that the Italian life insurance segment continues to exhibit an elevated level of concentration, by players and distribution channels. With roughly half of total life premiums written by three companies and distributed through bancassurance channels, these characteristics act as barriers to entry for new companies and prevent smaller participants from gaining market share.
To access a complimentary copy of this special report, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=354173.
AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527087905/en/
Contacts
Andrea Porta Financial Analyst +31 20 808 1700 andrea.porta@ambest.com Jose Berenguer Associate Director, Analytics +31 20 808 2276jose.berenguer@ambest.com Richard Banks Director, Industry Research – EMEA +44 20 7397 0322 richard.banks@ambest.com Edem KuenyehiaDirector, Market Development & Communications+44 20 7397 0280 edem.kuenyehia@ambest.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Simplify Healthcare's Benefits1™.Medicare Drives Over 30% of Nationwide PBP Submissions to CMS, Marking Over 7 Years as a Trusted Industry Leader
AURORA, Ill., June 06, 2025--(BUSINESS WIRE)--Simplify Healthcare, a recognized leader in enterprise software solutions for Payers, proudly announces that its flagship platform, Benefits1™.Medicare, played a key role once again in streamlining over 30% of Medicare Advantage (MA) Plan Benefit Package (PBP) submissions to the Centers for Medicare & Medicaid Services (CMS) this year. This milestone highlights the platform's transformative impact on benefit plan management and its integral role in supporting Payers across the nation. Benefits1™.Medicare continues to be the industry leader, enabling large-scale CMS bid submissions successfully for over 7 years, while also importing data seamlessly from the CMS-PBP software. Designed to handle the complexities of bid submission and accessible immediately (benefit updates can be started at any time independent of HPMS releases), the platform continues to set the standard for speed, accuracy, and compliance in PBP submissions with its seamless integration, robust reporting, global data updates, secure user roles, workflow automation and audit tracking capabilities. "Our customers relied on Benefits1™.Medicare to streamline over 30% of nationwide PBP submissions—proof of the trust we've earned and the efficiency our platform delivers year after year." — Ramesh Padri, VP of Product Delivery at Simplify Healthcare. "Managing the full Medicare Advantage lifecycle—from bids to digital delivery—makes Benefits1™.Medicare truly stand out in helping Payers drive value and improve member experiences." — Tasneem Chital, VP of Government Markets at Simplify Healthcare. Industry Leadership Through Customer Focus As healthcare organizations face increasing operational and regulatory challenges, Benefits1™.Medicare offers an effective solution that simplifies workflows while driving greater organizational efficiency. "This milestone reflects our long-standing commitment of partnering with health plans to successfully manage bid submissions. We bring the full stack partnership experience — people, thought leaders, product, and technology— towards delivering a superior bid submission experience for our customers." — Nirnay Patel, EVP & GM of Benefits1™ at Simplify Healthcare. About Simplify Healthcare Simplify Healthcare powers connected benefits and provider journeys for Payers through a scalable, enterprise-grade, secure, compliant, and configurable cloud-based software platform — Simplify Health Cloud™. We offer highly scalable, technology-centered document and translation management services to Payers through Simplify Docs™. We also empower industries with AI-native SaaS solutions designed to build and deploy digital solutions faster, better, and with embedded AI through SimplifyX™. View source version on Contacts Simplify HealthcarePhone: (844) 720-6678Email: info@
Yahoo
an hour ago
- Yahoo
AM Best Affirms Credit Ratings of Blue Whale Re Ltd.
OLDWICK, N.J., June 06, 2025--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Blue Whale's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings also reflect Blue Whale's function as the only captive insurer for Pfizer Inc. (Pfizer) [NYSE: PFE], a global pharmaceutical company. As Blue Whale insures or reinsures Pfizer's global property exposures, it plays a strategic and critical role in Pfizer's overall ERM in protecting the Pfizer enterprise's assets. Blue Whale provides substantial retentions in coverages for Pfizer, augmenting significant reinsurance capacity. In recent years of hard market conditions, Blue Whale also has opted to participate in small slices of its catastrophe tower as an economic efficiency for the Pfizer enterprise. It also offers capacity for cyber liability coverage when required by hard market pricing. The reinsurance program is appropriate and diverse, providing ample coverage for all its lines of business. AM Best recognizes the quality of the reinsurers and the substantial financial resources and assistance available to the captive as part of Pfizer. The captive covers low frequency/high severity exposures in which the losses have not compromised its strong operating performance nor profitability of the company. The stable outlooks reflect AM Best's view that the company will continue to generate operating results that engender supportive capitalization for the ratings. Additionally, AM Best expects Pfizer's ability and willingness to support Blue Whale, an integral part of Pfizer's corporate ERM infrastructure and program, will not change. AM Best remains the leading rating agency of alternative risk transfer entities, with more than 200 such vehicles rated in the United States and throughout the world. For current Best's Credit Ratings and independent data on the captive and alternative risk transfer insurance market, please visit This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Kourtnie Beckwith Senior Financial Analyst +1 908 882 1649 Daniel Teclaw Director +1 908 882 2390 Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 Al Slavin Senior Public Relations Specialist +1 908 882 2318 Connectez-vous pour accéder à votre portefeuille
